Clinical trials: Amyloid-beta
Amyloid-beta
Modulation of CSF Amyloid-beta Concentrations Via Behavioral Sleep Deprivation and Pharmacological Sleep Induction
The purpose of this study is to change the concentration of amyloid-beta in human cerebrospinal fluid (CSF) through modulation of the sleep-wake cycle.
- Trial name
- NCT02063217
- Testing
- Sodium Oxybate, Sleep deprivation
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Mild Cognitive Impairment
Beta-Amyloid Imaging With [18F]NAV4694 PET in Predicting Progression to AD in Subjects MCI
To investigate whether [18F]NAV4694 positron emission tomography (PET) scan findings have the ability to distinguish subjects with mild cognitive impairment (MCI) who progress to Alzheimer's disease (AD) from those who do not.
- Trial name
- NAV4-04 (NCT01812213)
- Testing
- [18F]NAV4694
- Where
- 11 sites in United States
- Volunteers
- 76 people
- Sponsor
- Navidea Biopharmaceuticals
Alzheimer Disease, Amyloid Beta-Protein
Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers
The aim of this study is to evaluate the efficacy, safety of a single dose of BAY 94-9172 (ZK 6013443) as an investigational medicinal product (IMP) in detecting cerebral protein-plaque (amyloid beta) with positron emission…
- Trial name
- NCT00750282
- Testing
- Florbetaben (BAY94-9172)
- Where
- 23 sites in United States, Australia and 3 more
- Volunteers
- 422 people
- Sponsor
- Lantheus Biosciences Ltd.
Alzheimer's Disease
Statin Effects on Beta-Amyloid and Cerebral Perfusion in Adults at Risk for Alzheimer's Disease
The purpose of the research is to see how simvastatin affects a substance in the body called beta-amyloid. Beta-amyloid is found in the brain and in the liquid around the brain and spinal cord.
- Trial name
- SHARP (NCT00939822)
- Testing
- Simvastatin
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Amyloid Beta Protein
Escitalopram Effects on CSF Amyloid Beta
Alzheimers disease (AD) is a devastating illness, estimated to affect 5 million patients in the United States alone and projected to increase dramatically over the next decades as the population ages unless preventive measures…
- Trial name
- NCT02161458
- Testing
- Escitalopram 20mg for 2 weeks, Escitalopram 20mg for 8 weeks, Escitalopram 30mg for 8 weeks
- Where
- 2 sites in United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Alzheimer's Disease, Mild Cognitive Impairment
Influence of Beta Amyloid Imaging on Care of Patients Cognitive Complaints.
When older patients develop cognitive problems - like memory loss - there may be any of several underlying causes, sometimes occurring in combination.
- Trial name
- NCT02309723
- Testing
- Beta amyloid imaging
- Where
- United States
- Volunteers
- 315 people, healthy volunteers welcome
- Sponsor
- Tufts Medical Center
Subjective Memory Loss in Older Persons
Study of the Effects of Cerefolin NAC on Inflammation Blood Markers in Older Individuals With Memory Complaints
The purpose of this six-month research study is to determine if Cerefolin NAC reduces levels of substances in the blood that may be associated with thinking ability and the health of brain cells in subjects with memory concerns…
- Trial name
- NCT00597376
- Testing
- Cerefolin NAC (a medical food)
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Rush University Medical Center
Insomnia
SIESTA: Sleep Intervention to Enhance Cognitive Status and Reduce Beta Amyloid
The objective of this study is to compare the efficacy of a sleep intervention on improving cognitive function in older adults with symptoms of insomnia, determine the association between change in sleep measures and change in…
- Trial name
- NCT03954210
- Testing
- Cognitive Behavioral Therapy for Insomnia (CBT-I), Sleep and Lifestyle Education
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Kansas Medical Center
Alzheimer Disease, Amyloid Beta-Protein
Florbetaben (BAY94-9172) PET (Positron Emission Tomography) Imaging in MCI (Mild Cognitive Impairment) Patients
The aim of the study is to investigate whether Florbetaben (BAY94-9172)positron emission tomography (PET) is able to distinguish between subjects with mild cognitive impairment (MCI) progressing to Alzheimer's disease (AD) from…
- Trial name
- NCT01138111
- Testing
- Florbetaben (BAY94-9172)
- Where
- Australia
- Volunteers
- 45 people
- Sponsor
- Lantheus Biosciences Ltd.
Alzheimer's Disease
Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age
The study determined the safety of CNP520 in healthy elderly over 3 months. Data relevant for Pharmacokinetic/Pharmacodynamic modeling were obtained in order to define the target dose in subsequent efficacy studies.
- Trial name
- NCT02576639
- Testing
- CNP520
- Where
- 11 sites in United States, Belgium and 3 more
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Down Syndrome, Amyloid Beta-protein
Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid.
To determine the sensitivity of the visual assessment of BAY94-9172 PET images in detecting cerebral β-amyloid in individuals with Down Syndrome (DS) and specificity in individuals without DS.
- Trial name
- NCT00928304
- Testing
- Florbetaben (BAY94-9172)
- Where
- 2 sites in United States
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Lantheus Biosciences Ltd.
Hypertension
Hypertension, Intracranial Pulsatility and Brain Amyloid-beta Accumulation in Older Adults (HIPAC Trial)
The aim of this study is to determine if lowering blood pressure using FDA approved medication (antihypertensive drugs) alters brain pulsatility and reduces brain amyloid beta protein accumulation in older adults.
- Trial name
- HIPAC (NCT03354143)
- Testing
- Standard Care, Intensive Treatment
- Where
- United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Alzheimer's Disease
Efficacy and Safety of Plasma Exchange With 5% Albumin in Beta-amyloid Peptide Clearance in Cerebral Spinal Fluid
The purpose of this study was to evaluate the efficacy and safety of plasma exchange with 5% albumin in beta-amyloid peptide clearance in cerebrospinal fluid, and its effects in patients with mild-moderate Alzheimer's disease.
- Trial name
- NCT00742417
- Testing
- Albutein 5%, Control
- Where
- 4 sites in United States, Spain
- Volunteers
- 42 people
- Sponsor
- Instituto Grifols, S.A.
Amyloid-beta
Sleep Quality and Amyloid-Beta Kinetics
The purpose of this study is to change the concentration of amyloid-beta in human cerebrospinal fluid (CSF) by modification of sleep efficiency.
- Trial name
- NCT03077620
- Testing
- Suvorexant
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Mild Cognitive Impairment
Candesartan's Effects on Alzheimer's Disease And Related Biomarkers
This study is intended to investigate the safety of candesartan, a blood pressure medication, in non-hypertensive individuals who have mild cognitive impairment (MCI) due to Alzheimer's disease and its effect on disease…
- Trial name
- CEDAR (NCT02646982)
- Testing
- Candesartan
- Where
- 2 sites in United States
- Volunteers
- 77 people
- Sponsor
- Emory University
Mild Cognitive Impairment
Feasibility of Gamma Transcranial Alternating Current Stimulation to Reduce Beta-amyloid Load and Improve Memory
This project assessed the feasibility of transcranial alternating current stimulation in the gamma band to lower beta-amyloid load and improve memory performance.
- Trial name
- NCT04646499
- Testing
- Transcranial alternating current stimulation
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Parkinson's Disease
Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients
The primary aim of this study is to compare regional amyloid burden in Parkinson's disease (PD) to normal control subjects. We hypothesize that there will be significant differences in overall amyloid burden in PD patients…
- Trial name
- NCT00857532
- Testing
- florbetapir F 18
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer's Disease
A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease
The purpose of this study is to evaluate the changes in the cognitive, functional, behavioral and global domains based on the different applicable psychometric batteries and scales.
- Trial name
- AMBAR (NCT01561053)
- Testing
- Albumin 5%, Albumin 20%, Immunoglobulin
- Where
- 40 sites in United States, Spain
- Volunteers
- 347 people
- Sponsor
- Instituto Grifols, S.A.
Alzheimer's Disease
Phase II Study of Intravenous Immunoglobulin (IVIg) for Alzheimer's Disease
The overall goal of this double-blind Phase II study is to evaluate the safety, efficacy and biological mechanisms of action of Intravenous Immunoglobulin (IVIg) in the treatment of mild to moderate stage Alzheimer's disease…
- Trial name
- NCT00299988
- Testing
- Intravenous Immunoglobulin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Weill Medical College of Cornell University
Alzheimer Disease
Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology
To determine the sensitivity and specificity of the visual assessment of tracer uptake in the Florbetaben PET images compared to histological verification of the presence or absence of cerebral β-amyloid in the respective…
- Trial name
- NCT01020838
- Testing
- Florbetaben (BAY94-9172)
- Where
- 19 sites in United States, Australia and 3 more
- Volunteers
- 218 people
- Sponsor
- Lantheus Biosciences Ltd.